Inavolisib (Itovebi) Patient Management

This document provides a comprehensive overview of the Positive Quality Intervention (PQI) for managing patients receiving Inavolisib (Itovebi™), a drug approved for treating hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA mutations. It includes guidelines for patient selection, dosing, safety management, and the role of a multidisciplinary team in treatment. The document emphasizes the importance of proactive monitoring and patient education to manage adverse events like hyperglycemia and mucositis, ensuring effective and safe therapy.